Skip to main content

Gefitinib/osimertinib

Cell transformation from lung adenocarcinoma into metastatic squamous-cell carcinoma and sarcomatoid carcinoma, and drug resistance: case report

This is a preview of subscription content, access via your institution.

Reference

  • Lee PH, et al. Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report. Clinical Lung Cancer 22: e536-e541, No. 4, Jul 2021. Available from: URL: http://doi.org/10.1016/j.cllc.2020.06.026

Download references

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gefitinib/osimertinib. Reactions Weekly 1894, 161 (2022). https://doi.org/10.1007/s40278-022-10274-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-10274-2